US drugmakers are betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... clinical development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, revolves around HS-20094 ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals ... exclusive rights for the clinical development and commercialization of a new obesity drug candidate outside of China. The deal, announced Monday, ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage ...